Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.75 USD | +6.68% | +15.93% | +288.51% |
Mar. 06 | HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating | MT |
Mar. 01 | Sector Update: Health Care Stocks Rising Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 242K | Sales 2025 * | 66.67K | Capitalization | 257M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -57M | EV / Sales 2024 * | 1,059 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3,853 x |
P/E ratio 2024 * |
-5.9
x | P/E ratio 2025 * |
-5.46
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.32% |
Latest transcript on Cardiff Oncology, Inc.
1 day | +6.68% | ||
1 week | +15.93% | ||
Current month | +225.78% | ||
1 month | +223.03% | ||
3 months | +278.29% | ||
6 months | +259.38% | ||
Current year | +288.51% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 5.75 | +6.68% | 1,766,935 |
24-03-26 | 5.39 | -8.80% | 1,449,028 |
24-03-25 | 5.91 | +1.03% | 1,971,677 |
24-03-22 | 5.85 | +13.81% | 2,737,034 |
24-03-21 | 5.14 | +3.63% | 795,514 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+288.51% | 257M | |
+9.16% | 45.97B | |
+53.69% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |